Waldenström macroglobulinemia is a rare blood cancer that usually affects older adults. It often grows slowly, and early symptoms of Waldenström macroglobulinemia can include tiredness, weakness, easy bruising, weight loss, or blurry vision. Many people live with Waldenström macroglobulinemia for years, but some need treatment soon after diagnosis. Not everyone will have the same experience. Treatment often includes medicines that target cancer cells, immunotherapy, or chemotherapy, and outlook and survival can vary based on how active the disease is and a person’s overall health.
How many people live with Waldenström macroglobulinemia?
Worldwide, about 1.6 million people were living within 5 years of a diagnosis of the broader blood cancer group called non-Hodgkin lymphoma, and because Waldenström macroglobulinemia makes up about 1% to 2% of that group, this suggests roughly 16,000 to 32,000 people worldwide may be living with it (Global Cancer Observatory, 2024; American Cancer Society, 2024); this is an estimate, not a direct count. In the United States, about 750,000 people were living with non-Hodgkin lymphoma, so Waldenström macroglobulinemia likely accounts for roughly 7,500 to 15,000 people (National Cancer Institute SEER, 2024; American Cancer Society, 2024); this is also an estimate rather than a direct count.
Overview
Waldenström macroglobulinemiaSymptoms
Waldenström macroglobulinemia may cause tiredness, weakness, easy bruising or bleeding, weight loss, and repeated infections. Some people also notice headaches, blurred vision, dizziness, numbness or tingling, or swollen glands.
Outlook and prognosis
Waldenström macroglobulinemia often grows slowly, and many people live with it for years with monitoring and treatment as needed. Outlook varies by age, overall health, and how active the disease is when it is found.
Causes and risk factors
Waldenström macroglobulinemia usually develops from acquired gene changes in blood-forming cells, often including MYD88, rather than anything you did. Risk is higher with older age, male sex, White ancestry, and a family history of Waldenström macroglobulinemia or related blood cancers.
Genetic influences
Genetics matter in Waldenstrom macroglobulinemia, but most cases are not directly inherited. Many people with Waldenstrom macroglobulinemia have acquired gene changes in blood cells, while a small number may have a family history that slightly raises risk.
Diagnosis
Diagnosis of Waldenström macroglobulinemia usually starts with blood tests and a medical history. Doctors often confirm it with a bone marrow biopsy, and may use imaging tests to check lymph nodes, the spleen, or other organs.
Treatment and drugs
Treatment for Waldenström macroglobulinemia often depends on symptoms and blood thickness. Many people are monitored at first, while others need targeted drugs, chemotherapy, antibody treatment, or plasma exchange. Care also includes managing anemia, infections, and nerve symptoms.
Symptoms
Waldenström macroglobulinemia can build slowly, and some people have no symptoms at first. When symptoms do appear, they often come from blood becoming thicker than usual, a drop in healthy blood cells, or abnormal cells collecting in organs and nerves. The early symptoms of Waldenström macroglobulinemia can be easy to overlook because they may feel like ordinary tiredness, dizziness, or getting winded more easily. Symptoms vary from person to person and can change over time.
Feeling unusually tired is one of the most common symptoms of Waldenström macroglobulinemia. This often happens because there are not enough red blood cells to carry oxygen well, so even a short walk or a flight of stairs can leave you drained.
Some people notice shortness of breath, weakness, or a pounding heartbeat during everyday activity. These can go along with anemia, which means the body is not getting oxygen as efficiently as usual.
Nosebleeds, bleeding gums, or bruises that seem to appear more easily can happen in Waldenström macroglobulinemia. In some people, the blood does not flow or clot normally, which can also make cuts take longer to stop bleeding.
Headaches, dizziness, blurred vision, or ringing in the ears can happen when the blood becomes thicker than normal. Day to day, it can feel like a pressure headache that lingers or vision that turns hazy while reading or driving.
How people usually first notice Waldenström macroglobulinemia?
Waldenström macroglobulinemia is often first noticed quietly, not with one dramatic warning sign but with a slow buildup of symptoms that can be easy to brush off at first. Many people living with this condition first notice unusual tiredness, weakness, shortness of breath with activity, or looking pale because the bone marrow is not making enough healthy blood cells, while others may develop easy bruising, frequent nosebleeds, headaches, dizziness, blurred vision, or tingling in the hands and feet as the abnormal protein in the blood makes it thicker. Some people have no symptoms at all and only learn something is wrong after routine blood work, which is why these first signs of Waldenström macroglobulinemia can vary from very subtle to more noticeable.
Types of Waldenström macroglobulinemia
Waldenström macroglobulinemia can affect day-to-day life in different ways, from feeling unusually tired to getting headaches, dizziness, or tingling in the feet. Symptoms don’t always look the same for everyone. There are not well-established biological types of Waldenström macroglobulinemia used in everyday care, so doctors usually talk instead about the main symptom patterns and how active the disease is. For many, understanding these symptom patterns is the clearest way to make sense of the types of Waldenström macroglobulinemia people may hear about.
Asymptomatic
Some people have Waldenström macroglobulinemia found on blood tests before it causes noticeable problems. This is often called smoldering or asymptomatic disease, and people may feel completely well. Symptoms can still appear later, so regular follow-up matters.
Marrow-related
When the bone marrow is crowded by lymphoma cells, the body may make fewer healthy blood cells. This can lead to fatigue, weakness, shortness of breath, easy bruising, or more frequent infections. Many living with Waldenström macroglobulinemia first notice this pattern when everyday tasks suddenly feel harder.
Thick blood
The abnormal protein made in Waldenström macroglobulinemia can thicken the blood, a problem known as hyperviscosity. People may develop headaches, blurred vision, dizziness, nosebleeds, or a sense of mental fog. These symptoms need prompt medical attention because they can worsen quickly.
Nerve-related
Some people develop numbness, burning, or pins-and-needles feelings, usually in the feet and lower legs. This happens when the abnormal protein affects the nerves, so walking, balance, or fine hand tasks may become more difficult over time. The nerve symptoms can be mild at first and then slowly build.
Organ-related
Waldenström macroglobulinemia can sometimes cause swollen lymph nodes or enlargement of the liver or spleen. This may show up as belly fullness, discomfort under the ribs, or feeling full after eating only a small amount. Some may also have unplanned weight loss or night sweats along with these changes.
Cold-sensitive
In a smaller group of people, the abnormal protein behaves differently in cooler temperatures and can affect blood flow. Fingers or toes may become painful, pale, bluish, or numb in the cold, and some people notice unusual rashes or skin changes. Less frequent, but still important, are these symptoms because they can point to protein-related complications.
Can I slow down the onset of symptoms?
No one has shown that lifestyle changes or early treatment can meaningfully delay the start of symptoms in Waldenström macroglobulinemia, a slow-growing blood cancer, although general habits like staying active, not smoking, sleeping well, and managing heart health may still support your overall health. If this condition is found before it is causing problems, the usual medical approach is careful follow-up, often called watchful waiting, rather than preventive treatment, because starting treatment early has not been proven to stop symptoms from developing later. Research is ongoing, and while healthy habits may help you feel stronger, they cannot be counted on to prevent this condition or keep it from becoming active.
What genetics can tell you about symptoms
Yes. In Waldenstrom macroglobulinemia, certain gene changes in the cancer cells, especially changes called MYD88 and sometimes CXCR4, can shape how the disease shows up, including how active it is, how quickly it grows, and whether problems such as high blood thickness, enlarged lymph nodes, or low blood counts are more likely. Genetics cannot predict every symptom for every person, but it can give doctors useful clues about likely disease behavior, how early symptoms may appear, and which treatments may work best.
Causes and risk factors
The exact cause of Waldenström macroglobulinemia is often not clear, but it usually starts after acquired gene changes develop in certain white blood cells. The main risk factors for Waldenström macroglobulinemia are older age, being male, and having a close relative with this disease or a related blood disorder. Risk is also higher in people with IgM MGUS, a blood condition that can come before Waldenström macroglobulinemia. Some immune system disorders and hepatitis C infection may also play a part, but no single environmental or lifestyle cause has been clearly proven. Not everyone with the same risk develops the condition.
What are the most common causes or risk factors?
Doctors do not know one single cause of Waldenström macroglobulinemia, but it usually begins when certain infection-fighting white blood cells in the bone marrow develop gene changes over time. It is most often found in older adults, especially men, and risk is higher in people who have a close family member with this disease or with a related blood cancer. Another important risk factor is an earlier, usually symptom-free condition in which the body makes an unusual blood protein, which can sometimes be a first step before Waldenström macroglobulinemia develops.
Environmental and biological risk factors
Most risk factors for Waldenström macroglobulinemia are tied to biology rather than anything you did or did not do. Doctors often group risks into internal (biological) and external (environmental). For this condition, the strongest known risk factors for Waldenström macroglobulinemia are older age, male sex, White ancestry, a preexisting IgM MGUS blood finding, and some long-term immune system conditions. No single outside exposure has been clearly proven as a major cause.
Waldenström macroglobulinemia is much more common in older adults, and it is rarely diagnosed in younger people. The chance of developing it rises as bone marrow cells age and pick up changes over time.
People assigned male at birth develop this condition more often than people assigned female at birth. The reason is not fully understood, but this pattern has been seen consistently in large studies.
Waldenström macroglobulinemia is diagnosed more often in people of White ancestry than in many other racial or ethnic groups. This is a population pattern, not a rule for any one individual.
IgM MGUS is a blood finding where a small amount of one antibody protein is present without signs of cancer. Many people with IgM MGUS never develop problems, but it is the clearest known precursor that raises the chance of Waldenström macroglobulinemia later on.
Genetic risk factors
For many living with Waldenström macroglobulinemia, one of the first questions is whether it runs in families. Most cases are linked to DNA changes that arise in the abnormal blood cells during life, while some risk seems to come from an inherited family tendency. Most people do not inherit Waldenström macroglobulinemia directly from a parent. It’s usually a combination of influences rather than one clear cause.
MYD88 change: Most people with Waldenström macroglobulinemia have a change in a gene called MYD88 in the abnormal bone marrow cells. This is usually an acquired change, not one inherited from a parent, and it helps those cells keep growing.
CXCR4 change: Some people with Waldenström macroglobulinemia also have a change in a gene called CXCR4 in the same abnormal cells. This added change can affect how active the disease is and may influence response to some treatments.
Chromosome losses: Some cases include missing pieces of chromosomes, especially part of chromosome 6, inside the cancer cells. These are acquired DNA changes that can work alongside MYD88 or CXCR4 and further disrupt normal cell control.
Family history: Having a close relative with Waldenström macroglobulinemia or a related B-cell blood disorder can modestly raise risk. This is why family history is considered one of the genetic risk factors for Waldenström macroglobulinemia.
Inherited tendency: Researchers think some families pass down several small DNA differences that raise susceptibility, rather than one single gene causing the disease. Carrying a genetic change doesn’t guarantee the condition will appear, and most people with Waldenström macroglobulinemia do not inherit it in a simple pattern.
Lifestyle risk factors
There are no well-established lifestyle habits that are known to directly cause Waldenström macroglobulinemia. However, several day-to-day factors can influence symptoms, treatment tolerance, infection risk, and complications, which is an important part of how lifestyle affects Waldenström macroglobulinemia. In practice, lifestyle risk factors for Waldenström macroglobulinemia are less about triggering the cancer and more about worsening fatigue, neuropathy, cardiovascular strain, or recovery during treatment.
Smoking can worsen circulation and lung function, which may add to fatigue and reduce physical reserve during treatment. It may also increase infection risk and complicate recovery if anemia or other treatment-related side effects develop.
Heavy alcohol use can suppress bone marrow function and may worsen low blood counts or weakness. It can also aggravate nerve damage, which matters because Waldenström macroglobulinemia and some of its treatments can cause neuropathy.
Low activity levels can lead to deconditioning, poorer stamina, and more severe fatigue. Gentle regular movement may help preserve strength, balance, and daily function, especially if anemia or neuropathy is present.
Inadequate protein and calorie intake can make weight loss, weakness, and recovery harder during active disease or treatment. A diet low in nutrient-dense foods may also make it more difficult to cope with infections and treatment side effects.
Risk prevention
For most people, there is no proven way to prevent Waldenström macroglobulinemia. Many of its main risk factors, such as older age and family history, cannot be changed. Prevention is about lowering risk, not eliminating it completely. In practice, this usually means focusing on overall health and making sure possible early symptoms of Waldenström macroglobulinemia are checked without delay.
Waldenström macroglobulinemia cannot usually be prevented with a specific diet, supplement, or lifestyle change. That can feel frustrating, but it also means you should be cautious about products or programs that claim otherwise.
Some people develop a related blood finding called IgM MGUS before Waldenström macroglobulinemia appears. If you have been told you have this condition, regular blood tests and follow-up visits can help catch changes early.
Waldenström macroglobulinemia can run in some families, even though most cases happen without a strong inherited pattern. Knowing your family history can guide which preventive steps matter most.
New tiredness, easy bruising, frequent nosebleeds, numbness, or blurred vision should not be ignored, especially if they keep coming back. Getting symptoms checked early cannot prevent Waldenström macroglobulinemia, but it may reduce complications by leading to earlier diagnosis.
Can you prevent Waldenström macroglobulinemia?
No, there is no known way to fully prevent Waldenström macroglobulinemia, a rare slow-growing blood cancer. Doctors do not yet know exactly what causes it, and the main risk factors linked to it, such as older age and family history, are not things you can control. Healthy habits still matter for overall health, but they have not been proven to stop this condition from developing.
Transmission
Waldenström macroglobulinemia is not infectious, so it cannot be caught from someone else through touch, coughing, sex, shared food, or blood contact. If you are wondering about the genetic transmission of Waldenström macroglobulinemia, it is usually not directly passed from parent to child in the way some inherited conditions are.
Most people living with Waldenström macroglobulinemia develop it because of gene changes that happen over time in blood-forming cells during life, not because they inherited the disease itself. A close family history can slightly raise the chance of developing this rare blood cancer, but most relatives never get it, and many people with Waldenström macroglobulinemia have no known family history.
When to test your genes
There is no routine gene test to catch Waldenström macroglobulinemia early in otherwise healthy people. Genetic testing is most useful after it is suspected or diagnosed, because tumor testing for changes such as MYD88 and sometimes CXCR4 can help confirm the disease and guide treatment choices.
Diagnosis
Waldenström macroglobulinemia is often found after a blood test shows an unusual protein level, anemia, or other changes that need a closer look. Some people are checked because of tiredness, easy bruising, headaches, numbness, or blurred vision, while others have no symptoms at first. Doctors usually combine symptoms, blood work, and a bone marrow test to confirm the diagnosis of Waldenström macroglobulinemia.
Your doctor will ask about symptoms such as fatigue, nosebleeds, weight loss, infections, tingling, or vision changes. A detailed family and health history can help show whether the pattern fits Waldenström macroglobulinemia or points to another blood disorder.
The exam may look for swollen lymph nodes, an enlarged liver or spleen, signs of bleeding, or nerve problems. These findings cannot confirm the disease on their own, but they help guide the next tests.
Blood tests measure red cells, white cells, platelets, kidney function, and the level of a protein called IgM. They also check blood thickness and other markers, which is a key part of how Waldenström macroglobulinemia is diagnosed.
Special blood and urine tests identify the abnormal antibody made by the cancer cells and measure how much is present. This helps separate Waldenström macroglobulinemia from conditions with similar symptoms or lab results.
How is Waldenström macroglobulinemia diagnosed?
Doctors usually diagnose Waldenström macroglobulinemia with blood tests that show a very high level of a certain blood protein, often called IgM, along with problems such as low red blood cells or blood that has become too thick. The diagnosis is usually confirmed with a bone marrow test, where a small sample is taken from the soft center of a bone to look for the unusual white blood cells linked to this disease. Gene testing on the blood or bone marrow may also help support the diagnosis, and scans are sometimes used to check for swollen lymph nodes or an enlarged spleen or liver.
Stages of Waldenström macroglobulinemia
Waldenström macroglobulinemia does not have defined progression stages. That is because it is usually described by how active it is, what symptoms it is causing, and what blood and bone marrow tests show, rather than by a clear step-by-step pattern over time. Doctors usually start with a conversation about symptoms such as tiredness, easy bruising, headaches, or blurred vision, including any early symptoms of Waldenström macroglobulinemia that have been affecting daily life. Monitoring often includes blood tests, a bone marrow test, and checks for problems linked to thicker blood, anemia, swollen lymph nodes, or nerve symptoms.
Outlook and prognosis
The outlook for people with Waldenström macroglobulinemia is often relatively favorable compared with many other blood cancers, because it usually grows slowly and many patients can live for years with careful monitoring and treatment. Prognosis varies widely depending on age, overall health, tumor burden, anemia, platelet count, β2-microglobulin level, and whether complications such as hyperviscosity, neuropathy, or amyloidosis are present. Some people with smoldering disease may not need treatment right away, while others with symptomatic disease can respond well to modern therapies and have prolonged remissions, although relapse is common. Reported median overall survival is commonly around 8 to 12 years in broad patient groups, and outcomes may be longer in lower-risk patients treated with newer regimens. Death can result from progressive lymphoma, treatment complications, serious infections, or organ damage related to the disease, but many patients die of unrelated causes because the condition often follows a chronic course. Early recognition of symptoms, individualized therapy, and ongoing follow-up can significantly improve quality of life and long-term outcomes.
Long-term effects
Waldenström macroglobulinemia often unfolds slowly, but over time it can affect energy, nerves, circulation, and other organs. Many people live with it for years, sometimes with long stretches of stability and then periods when the disease becomes more active again. Long-term effects vary widely, and they partly depend on how much abnormal protein builds up in the blood and how much the bone marrow is involved. Some people have only mild changes for a long time, while others develop more noticeable complications.
Many people with Waldenström macroglobulinemia develop anemia, which means there are fewer red blood cells to carry oxygen. This can lead to lasting tiredness, shortness of breath, reduced stamina, and feeling worn out by everyday tasks.
The disease can damage nerves over time, especially in the feet and hands. This may cause numbness, tingling, burning pain, or trouble with balance, and these changes can sometimes become long lasting.
Waldenström macroglobulinemia can raise levels of an abnormal protein that makes blood thicker than usual. When that happens, people may have headaches, blurred vision, dizziness, or nosebleeds, and severe cases can affect blood flow to the brain or eyes.
Because the disease affects the immune system, some people get infections more easily or recover more slowly. Repeated sinus, chest, or other infections can become an ongoing issue over the years.
How is it to live with Waldenström macroglobulinemia?
Living with Waldenström macroglobulinemia can feel unpredictable because some people feel well for years with careful monitoring, while others deal with fatigue, weakness, nerve symptoms such as numbness or tingling, or problems linked to thicker blood, which can make daily routines more tiring and less reliable. For many, life becomes a balance between medical visits, blood tests, and treatment periods, with energy levels and symptoms shaping work, exercise, travel, and social plans. It often affects loved ones too, who may take on rides, appointments, and extra practical or emotional support, but many people with Waldenström macroglobulinemia are still able to keep meaningful routines and adapt well with the right care.
Treatment and drugs
Waldenström macroglobulinemia is usually treated based on how much it is affecting daily life, so some people are monitored for a time before treatment starts, while others need therapy sooner because of symptoms such as fatigue, nerve problems, bleeding, or blood that has become too thick. Common treatment for Waldenström macroglobulinemia includes medicines that target the cancer cells, often combined with other drugs that help them work better, and some people may also receive steroids or antibody-based treatment through a vein or by injection. If the blood becomes very thick, doctors can use a procedure called plasma exchange to quickly remove some of the extra protein and ease symptoms, but this does not treat the underlying cancer by itself. Not every treatment works the same way for every person, and care is often adjusted for age, overall health, gene changes in the cancer, and whether this is the first treatment or the disease has come back. For many people, treatment begins with small daily steps, including follow-up blood tests and talks with their care team about side effects, infection risk, and how well treatment is helping.
Can you cure Waldenström macroglobulinemia?
Waldenström macroglobulinemia is not usually considered curable at this time. But treatment can often control it for long periods, lower the harmful protein it makes in the blood, and ease symptoms so people can feel better and stay active. Many people living with this blood cancer have long stretches when it is quiet, and treatment can be changed over time if it starts causing problems again.
Non-drug treatment
Living with Waldenström macroglobulinemia can mean long stretches with few symptoms, followed by times when fatigue, infections, or nerve symptoms start to interfere with daily life. For many, treatment begins not at the pharmacy, but with careful monitoring and supportive care tailored to how the disease is affecting blood flow, blood counts, and energy levels. Non-drug options can also help when problems such as thickened blood, anemia, or reduced fitness become part of day-to-day life. The right plan varies, especially because some people need help soon after diagnosis while others may spend years with watchful follow-up alone.
Many people with Waldenström macroglobulinemia do not need treatment right away and are followed with regular visits, blood tests, and symptom checks. This watch-and-wait approach helps avoid unnecessary treatment while still catching changes such as worsening fatigue, weight loss, or early symptoms of Waldenström macroglobulinemia.
If the blood becomes too thick, a procedure called plasmapheresis can remove excess protein from the bloodstream fairly quickly. This may ease headaches, blurred vision, dizziness, or shortness of breath, but it does not treat the underlying cancer cells.
Some people with severe anemia may need red blood cell transfusions to improve oxygen delivery through the body. This can help with exhaustion, lightheadedness, and getting through simple activities like climbing stairs or grocery shopping.
Focused radiation may be used when Waldenström macroglobulinemia causes a painful enlarged lymph node, spleen-related pressure, or another localized problem. It is not a routine treatment for everyone, but it can help shrink tissue that is causing symptoms in one area.
Your genes may have an impact on how drugs work for you
For people living with Waldenström macroglobulinemia, small differences in the cancer cells can affect how well certain treatments work, so two people with the same diagnosis may not get the same benefit from the same medicine. In this condition, doctors sometimes look for well-known changes in the lymphoma cells before treatment, because these changes can help predict whether a targeted drug is likely to work well, work more slowly, or cause more side effects. This kind of gene-based treatment matching can be clinically useful in Waldenström macroglobulinemia, but it usually involves changes in the cancer cells rather than inherited traits passed down in a family.
Pharmacological treatments
Treatment for Waldenström macroglobulinemia depends on symptoms, blood counts, how thick the blood has become, and how quickly the condition is changing. Many people living with Waldenström macroglobulinemia do well with drug treatment when symptoms start to affect daily life, such as fatigue, weight loss, nerve symptoms, or frequent infections. First-line medications are those doctors usually try first, based on how well they work and the side effects they tend to cause. In urgent situations, treatment may also include plasma exchange to quickly lower very thick blood, but the medicines below are the main drug options.
Rituximab is a commonly used antibody drug for Waldenström macroglobulinemia that targets abnormal B cells. It may be used alone in milder cases, but it is often combined with other medicines for stronger and longer-lasting control.
Ibrutinib, zanubrutinib, and acalabrutinib are targeted drugs that block a signal the cancer cells use to survive. These medicines are often used as a first-line treatment for Waldenström macroglobulinemia or after other treatment stops working, especially when a slower, ongoing oral treatment is a good fit.
Bendamustine is a chemotherapy drug usually given with rituximab. This combination is widely used because it can work well for many people and may provide a long period before treatment is needed again.
Bortezomib is most often used with rituximab and dexamethasone, and carfilzomib or ixazomib may be used in some settings. These drugs can act relatively quickly, which can matter when symptoms are building fast or blood thickness is becoming a problem.
Genetic influences
Waldenström macroglobulinemia is often linked to gene changes inside the blood-forming cells themselves, especially an acquired change in a gene called MYD88, and some people also have a change in CXCR4. These changes usually happen during life rather than being passed down from a parent, so most people with Waldenström macroglobulinemia did not inherit the disease directly. Family history is one of the strongest clues to a genetic influence. People with a family history of Waldenström macroglobulinemia or related blood conditions may have a higher risk than the general population, although the condition is still uncommon. This suggests that inherited factors may help set the stage in some families, while other noninherited factors likely matter too. If Waldenström macroglobulinemia appears in more than one close relative, a hematologist or genetic counselor can help explain what that family pattern may mean.
Is Waldenström macroglobulinemia genetic?
Genetics matter in Waldenstrom macroglobulinemia, but most cases are not directly inherited. Many people with Waldenstrom macroglobulinemia have acquired gene changes in blood cells, while a small number may have a family history that slightly raises risk.
Having a genetic risk is not necessarily a diagnosis
Gene changes are a normal part of human biology and are common in the general population. Most of these variants do not directly affect health and are simply part of natural human diversity. For many genes, having a variant connected to a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, though, one well-understood variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Treatment for Waldenström macroglobulinemia is often guided by gene changes found in the cancer cells, not just by symptoms or blood test results. Doctors commonly check for changes in MYD88 and CXCR4 because these results can help show which targeted medicines are more likely to help. For example, many people living with Waldenström macroglobulinemia who have a MYD88 change respond well to drugs called BTK inhibitors, while those without that change may benefit more from a different treatment plan; a CXCR4 change can also make treatment response slower or less complete in some cases. Genetics is only one factor, though, and your age, symptoms, blood counts, nerve problems, and other health conditions still play a big part in treatment choices. Inherited drug-response genes usually matter less here than the tumor’s own gene changes, but genetic testing for Waldenström macroglobulinemia treatment can still help doctors choose therapy more precisely and reduce some of the guesswork.
Interactions with other conditions
People living with Waldenström macroglobulinemia may notice that other health problems feel harder to manage, especially when fatigue, anemia, or thicker-than-normal blood add strain to the body. If you also have heart or lung disease, for example, even routine activities like climbing stairs or carrying groceries can leave you more short of breath or lightheaded. Waldenström macroglobulinemia can also affect the immune system, so infections may happen more easily or hit harder, particularly during treatment. Doctors call it a comorbidity when two conditions occur together, and in Waldenström macroglobulinemia this can include nerve problems, bleeding issues, or immune-related conditions that add to day-to-day symptoms. Some people also develop problems linked to the abnormal protein made in this disease, which can affect nerves, the kidneys, or circulation and may overlap with early symptoms of Waldenström macroglobulinemia. Because these interactions can change which symptoms matter most and which treatments are safest, it is important for your care team to look at the whole picture, not just the blood cancer itself.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Waldenström macroglobulinemia?
Other blood and bone marrow conditions can look similar to Waldenström macroglobulinemia, especially multiple myeloma, some slow-growing non-Hodgkin lymphomas, and chronic lymphocytic leukemia, because they can also cause tiredness, weight loss, infections, swollen lymph nodes, nerve problems, or abnormal bleeding. Doctors may also need to rule out MGUS, a blood protein condition that is not full cancer but can look similar on blood tests, as well as common non-cancer causes of anemia or numbness and tingling. Because these symptoms overlap so much, blood tests, a bone marrow test, and sometimes imaging are often needed to tell them apart.
History
People living with Waldenström macroglobulinemia may spend months or even years trying to make sense of vague problems like unusual tiredness, headaches, easy bruising, or feeling short of breath with everyday activity. That partly explains why the condition took time to understand. Doctors first recognized that some people had a slow-growing blood cancer linked to unusually thick blood and very high levels of one kind of antibody, but early descriptions focused more on what was seen in the clinic than on the underlying cause.
In 1944, Swedish physician Jan G. Waldenström described two patients with bleeding, swollen lymph nodes, anemia, and a blood protein pattern that looked different from other illnesses known at the time. From these first observations, doctors gradually realized this was its own condition, now called Waldenström macroglobulinemia. Over time, Waldenström macroglobulinemia was separated from other blood disorders that can seem similar, especially multiple myeloma and other lymphomas, because it behaves differently and usually grows more slowly.
As laboratory testing improved in the second half of the 20th century, doctors became better at measuring abnormal antibodies in the blood and examining bone marrow samples. This helped explain why some people with Waldenström macroglobulinemia develop symptoms related to thicker blood, nerve problems, or low blood counts, while others are diagnosed before they feel ill. In recent decades, awareness has grown, and researchers have also identified genetic changes in the cancer cells that help explain how the disease develops, though those findings are discussed separately from its history.
Today, the history of Waldenström macroglobulinemia matters because it shaped how the condition is diagnosed and followed. What was once a puzzling cluster of symptoms is now a recognized blood cancer with clearer testing, better monitoring, and more treatment options. For many, this means early symptoms of Waldenström macroglobulinemia are more likely to be connected to the right diagnosis than they were in the past.